QVQ Licenses Monod Bio's LuxSit™ Pro Luciferase to Measure Target Engagement of Single-Domain Antibodies
– Agreement enables QVQ to offer LuxSit Pro-based target engagement assays as part of its single-domain antibody discovery services
SEATTLE, Nov. 17, 2026 /PRNewswire/ -- QVQ, a Netherlands-based contract research organization specializing in single-domain antibody (sdAb) discovery, and Monod Bio, a Seattle-based AI-enabled protein design company, today announced a non-exclusive licensing agreement covering Monod Bio's LuxSit Pro de novo luciferase and its split components.
Under the terms of the agreement, QVQ may incorporate the technology into fee-for-service, research-use-only assays that screen and characterize sdAb target binding for its customers. The agreement expands QVQ's molecular pharmacology and lead discovery services.
LuxSit Pro is an AI-designed, light-generating reporter that QVQ will apply in two formats. In a split format, two LuxSit Pro fragments combine when an sdAb binds its target, restoring luciferase activity and producing a luminescent signal. In a bioluminescence resonance energy transfer (BRET) format, LuxSit Pro acts as the energy donor for a fluorophore-labeled sdAb. Together, the formats offer orthogonal approaches for characterizing lead candidates, while the split format supports high-throughput screening of large candidate sets, including computationally generated binders.
"Adding LuxSit Pro to our toolkit strengthens our ability to identify and characterize single-domain antibodies that truly engage their targets in a native cellular context. This technology complements our existing molecular pharmacology capabilities and supports both high-throughput screening and in-depth lead characterization," said Raimond Heukers, PhD, Chief Scientific Officer, of QVQ.
"We designed LuxSit Pro to be a useful component of real research workflows, and QVQ's sdAb expertise shows what it can do in target engagement studies," said Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio. "This agreement reinforces the value of our Monod Inside model for bringing AI-designed proteins into commercial services."
About Monod Bio
Monod Bio uses AI-powered de novo protein design to create binders, biosensors, and other functional proteins for research and diagnostic applications. Through its Monod Inside model, Monod Bio partners with life science companies to integrate its technologies into products and services. For more information, visit monod.bio.
About QVQ
QVQ is a contract research organization (CRO) based in the Netherlands, specialized in the discovery of single-domain antibodies (sdAbs, also known as VHHs or nanobodies). QVQ's lead discovery workflow covers immunization, library construction, selection, screening, and validation of lead clones, complemented by extensive molecular pharmacological characterization services, including target engagement, epitope binning, antagonism and functional assays. QVQ has also developed several proprietary computational pipelines for optimizing sdAbs, including structural modelling, affinity maturation, humanization, developability improvement and computational de novo binder generation.
SOURCE Monod Bio; QVQ


Share this article